Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison

Journal of Clinical Psychopharmacology

Volumn 16, Issue 2, 1996, Pages 121-129

  Koran, Lorrin M ^a,b,c,d,e,f   Mcelroy, Susan L ^a,b,c,d,e,f   Davidson, Jonathan R T ^a,b,c,d,e,f   Rasmussen, Steven A ^a,b,c,d,e,f   Hollander, Eric ^a,b,c,d,e,f   Jenike, Michael A ^a,b,c,d,e,f  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d BUTLER HOSPITAL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUVOXAMINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; OBSESSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CLOMIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY INVENTORY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0029947585     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199604000-00004     Document Type: Article

References (35)

1. Robins LN, Heizer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Regier DA. Lifetime prevalence of specific psychiatric disorders three sites. Arch Gen Psychiatry 1984;41:958-67.
2. Jenike MA. Obsessive-compulsive and related disorders: a hidden epidemic. N Engl J Med 1989;321:539-41.
3. Zetin M, Kramer MA. Obsessive-compulsive disorder. Hosp Community Psychiatry 1992;43:689-99.
4. Dupont RL, Rice DP, Shiraki S, Rowland CR. Economic costs of obsessive-compulsive disorder. Med Interface 1995;8:102-9.
5. Clomipramine Collaborative Study Group. Clomipraimne in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
6. Goodman WK, McDougle CJ. Serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Ann Clin Psychiatry 1990;3:173-81.
7. Hollander E. Obsessive-compulsive spectrum disorders: an overview. Psychiatr Ann 1993;23:355-8.
8. McDougle CJ, Goodman WK, Price LH. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry 1993;26[suppl]:24-9.
9. Winslow JT, Insel TR. Neurobiology of obsessive-compulsive dis-order: a possible role for serotonin. J Clin Psychiatry 1990;51[suppl 8]:27-31.
10. Dominguez RA. Serotonergic antidepressants and their efficacy in obsessive-compulsive disorder. J Clin Psychiatry 1992;53[suppl 10]:56-9.
11. Hrdina PD. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine. J Psychiatry Neurosci 1991;16[2 suppl 1]:10-8.
12. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987;144:1543-8.
13. Price LJ, Goodman WK, Charney DS, Rasmussen SA, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987;144:1059-61.
14. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry 1989;46:36-44.
15. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-15.
16. Mallya GK, White K, Waternaux, Quay S. Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 1992;4:77-80.
17. Montgomery SA, Manceaux A. Fluvoxamine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1992;7[suppl 1]:5-9.
18. Smeraldi E, Erzegovesi S, Bianchi I, Pasquali L, Cocchi S, Ronchi P. Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 1993;8:63-5.
19. Tamimi RR, Mavissakalian MR, Jones B, Olson S. Clomipramine versus fluvoxamine in obsessive-compulsive disorder. Ann Clin Psychiatry 1991;3:275-9.
20. Freeman CPL, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;44:1-5.
21. Goodman W, Price L, Rasmussen S, Mazure C, Leischmann R, Hill C, Heninger G, Charney D. The Yale-Brown obsessive compulsive scale (Y-BOCS). Part I. Development, use and reliability. Arch Gen Psychiatry 1989a;46:1006-11.
22. Goodman W, Price L, Rasmussen S, Mazure C, Leischmann R, Hill C, Heninger G, Charney D. The Yale-Brown obsessive compulsive scale (Y-BOCS). Part II. Validity. Arch Gen Psychiatry 1989b;46:1012-6.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institutes of Mental Health, U.S. Department of Health, Education, and Welfare. Publication no. 76-338, 1976.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
25. Nelson JC, Jatlow PI, Quinlan DM. Subjective complaints during desipramine treatment. Arch Gen Psychiatry 1984;41:55-9.
26. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorden comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-85.
27. Wagner W, Plekkenpol B, Gray TE, Blaskamp H, Essers H. Review of fluvoxamine safety database. Drugs 1992;43[suppl 2]:48-54.
28. Roos JC. Cardiac effects of the antidepressant drugs: a compart son of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 1983;15[suppl]:439S-445S.
29. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear K, Goodman W, Genduso LA. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
30. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ, The Lilly European OCD Study Group. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3:143-52.
31. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
32. Malan D. Individual psychotherapy and the science of psychodynamics. London: Butterworths, 1979:218-9.
33. Jenike MA. Obsessive-compulsive disorder efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993;29:487-99.
34. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60.
35. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder, behavioral and biological results. Arch Gen Psychiatry 1990;47:926-32.